Randhawa Amarita S, Babalola Olakiitan, Henney Zachary, Miller Michele, Nelson Tanya, Oza Meerat, Patel Chandni, Randhawa Anupma S, Riley Joyce, Snyder Scott, So Sherri
Purdue Pharma LP, Stamford, CT, USA
Celgene Corporation, Berkeley Heights, NJ, USA.
Ann Pharmacother. 2016 May;50(5):352-9. doi: 10.1177/1060028016635196. Epub 2016 Feb 25.
Online drug information compendia (ODIC) are valuable tools that health care professionals (HCPs) and consumers use to educate themselves on pharmaceutical products. Research suggests that these resources, although informative and easily accessible, may contain misinformation, posing risk for product misuse and patient harm.
Evaluate drug summaries within ODIC for accuracy and completeness and identify product-specific misinformation.
Between August 2014 and January 2015, medical information (MI) specialists from 11 pharmaceutical/biotechnology companies systematically evaluated 270 drug summaries within 5 commonly used ODIC for misinformation. Using a standardized approach, errors were identified; classified as inaccurate, incomplete, or omitted; and categorized per sections of the Full Prescribing Information (FPI). On review of each drug summary, content-correction requests were proposed and supported by the respective product's FPI.
Across the 270 drug summaries reviewed within the 5 compendia, the median of the total number of errors identified was 782, with the greatest number of errors occurring in the categories of Dosage and Administration, Patient Education, and Warnings and Precautions. The majority of errors were classified as incomplete, followed by inaccurate and omitted.
This analysis demonstrates that ODIC may contain misinformation. HCPs and consumers should be aware of the potential for misinformation and consider more than 1 drug information resource, including the FPI and Medication Guide as well as pharmaceutical/biotechnology companies' MI departments, to obtain unbiased, accurate, and complete product-specific drug information to help support the safe and effective use of prescription drug products.
在线药品信息汇编（ODIC）是医疗保健专业人员（HCP）和消费者用于自我了解药品的宝贵工具。研究表明，这些资源虽然信息丰富且易于获取，但可能包含错误信息，存在产品误用和患者伤害的风险。
评估ODIC中的药品概述的准确性和完整性，并识别特定产品的错误信息。
在2014年8月至2015年1月期间，来自11家制药/生物技术公司的医学信息（MI）专家系统地评估了5种常用ODIC中的270份药品概述是否存在错误信息。采用标准化方法识别错误；将其分类为不准确、不完整或遗漏；并按完整处方信息（FPI）的各部分进行分类。在审查每份药品概述时，根据相应产品的FPI提出并支持内容更正请求。
在这5个汇编中审查的270份药品概述中，识别出的错误总数中位数为782，其中错误数量最多的类别是用法用量、患者教育以及警告和注意事项。大多数错误被分类为不完整，其次是不准确和遗漏。
该分析表明ODIC可能包含错误信息。HCP和消费者应意识到存在错误信息的可能性，并考虑使用多种药品信息资源，包括FPI和用药指南以及制药/生物技术公司的MI部门，以获取公正、准确和完整的特定产品药品信息，以帮助支持处方药产品的安全有效使用。
